Validair expands despite the recession
Even though the recession has bitten, Validair has expanded its business over the last 18 months with two acquisitions in the field of validation and construction packages
Based in Darlington, Diamond Scientific was acquired in February 2009, and dovetails neatly into Validair’s testing and certification arm – Validair Euro. Towards the end of last year, the other acquisition took place – that of Malvern-based Facility Monitoring Systems. With its expertise in supply, installation, servicing and calibration of continuous and compliant environmental monitoring systems, this company will fit into the Validair Projects side of the business and will enhance the scope of services offered by the Validair Group of Companies.
Validair Euro was established in 1989 as a validation test house within the contamination control industry. In early 2003 the company’s services further expanded with the creation of Validair Projects – a company dedicated to providing cleanroom design consultancy, construction and project management services.
Although Validair has always offered its services across the entire British Isles from its base in Wrotham, Kent, the acquisition of these two new companies gives ideal geographical sites in the Midlands and the North of England, for even quicker response to customers’ needs.
This was an important factor, as Validair director Steve Ward explains: 'We have always worked nationwide, but there are many potential clients who might have a perception of problems if you don’t have an office nearby.
'The other real advantage,' he continues, 'is that we add to our already extensive skill bases. Training up people to do the work is time-consuming, but having additional fully qualified personnel overnight is a massive benefit.”
The services on offer from the Validair Group of Companies are extensive: the company describes itself as a ‘one-stop shop’ in the field of clean and controlled environments.
Validair brings to the marketplace everything from feasibility studies and design to construction, testing and validation of the facility, including the installation of environmental monitoring systems as an integral part of the cleanroom or as a stand-alone system supply direct to the end user or project developer.
Commenting on the acquisitions, Ward says: 'While the country may have had to contend with a recession, we have managed to continue to build our business – the acquisition of Diamond Scientific and Facility Monitoring Systems is further evidence of our continued success.'
You may also like
Trending Articles
You may also like
Regulatory
UK REACH ATRm: CBA welcomes progress but warns of significant hurdles ahead
The Chemical Business Association has acknowledged long-awaited movement on the UK REACH Alternative Transitional Registration model following DEFRA's consultation response, but cautioned that cost burdens likely running into hundreds of millions of pounds
Regulatory
Lonza Nominates Stephen Fry as Independent Board Member
Basel, Switzerland, 31 March 2026 – The Lonza Board of Directors today announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committeex
Regulatory
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions
Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Regulatory
FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths
The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment